Log in to save to my catalogue

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-s...

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-s...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1555409613

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

About this item

Full title

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2014-08, Vol.384 (9944), p.665-673

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. Methods In this multi...

Alternative Titles

Full title

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1555409613

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1555409613

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(14)60845-X

How to access this item